| Nervous System Neoplasms |
NCT00652990: Sirolimus to Treat Plexiform Neurofibromas in Patients With Neurofibromatosis Type I |
|
|
| Active, not recruiting | 2 | 18 | US | Sirolimus | University of Alabama at Birmingham, National Cancer Institute (NCI) | Neurofibromatosis Type 1, Plexiform Neurofibromas, Paraspinal Plexiform Neurofibromas | 08/14 | 08/14 | | |
NCT00831324: Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma |
|
|
| Recruiting | 2 | 60 | US | everolimus, immunohistochemistry staining method, laboratory biomarker analysis | University of California, San Francisco | Brain Tumor | 01/16 | 01/17 | | |
| Recruiting | 2 | 18 | US | AZD6244 | National Cancer Institute (NCI) | Optic Glioma, Pilocytic Astrocytoma, Low Grade Glioma, Fibriullary Astrocytoma | 10/16 | 11/18 | | |
NCT01373333: Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome |
|
|
| No Longer Available | N/A | | US | 3,4 DAP | The Cleveland Clinic | Lambert-Eaton Myasthenic Syndrome | 09/12 | | | |
NCT01378546: Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP |
|
|
| No Longer Available | N/A | | US | 3,4-diaminopyridine | Louis H. Weimer, MD | Lambert Eaton Myasthenic Syndrome (LEMS) | 05/15 | | | |
NCT01117168: Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group |
|
|
| Active, not recruiting | N/A | 57816 | US | | Children's Oncology Group, National Cancer Institute (NCI) | Pediatric Cancer, Leukemia, Sarcoma, Brain Tumors | 12/30 | 12/30 | | |
NCT00683319: Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy |
|
|
| Active, not recruiting | N/A | 50 | Europe | carboplatin, cisplatin, cyclophosphamide, methotrexate, vincristine sulfate, adjuvant therapy, cognitive assessment, magnetic resonance imaging, magnetic resonance spectroscopic imaging, quality-of-life assessment | Children's Cancer and Leukaemia Group | Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Ototoxicity | 03/34 | | | |